Alembic Pharmaceuticals debuts in U.S. with Namenda generic

GUJARAT, India — Alembic Pharmaceuticals has kicked off its operations in the United States with the launch of its memantine hydrochloride tablets, a generic of Namenda. The drug, which is indicated to treat Alzheimer’s diseases and dementia, will be available in 5- and 10-mg dosage strengths.

“We are very excited about the launch of Memantine tablets and the opportunity to provide patients an affordable therapeutic option” Craig Salmon, Alembic’s president of U.S. operations said.  “This is an important step for Alembic and the first of many new products to be launched into the U.S. market in the immediate future.”